Research theme for competitive and other funds (2):
2023 - 2026 悪性髄膜腫に対する末梢血および臍帯血由来NK細胞を用いた免疫細胞療法の開発
2022 - 2025 TIGITノックアウトヒトNK細胞を用いた膠芽腫に対する新規治療法の開発
Papers (31):
Ryosuke Matsuda, Ryosuke Maeoka, Takayuki Morimoto, Tsutomu Nakazawa, Noriaki Tokuda, Masashi Kotsugi, Yasuhiro Takeshima, Kentaro Tamura, Shuichi Yamada, Fumihiko Nishimura, et al. Effect of Intraoperative Ventricular Opening on Recurrence Patterns Following Bis-Chloroethyl-Nitrosourea Wafer Implantation for Newly Diagnosed Glioblastoma. Journal of Korean Neurosurgical Society. 2024
Tsutomu Nakazawa(corresponding author), Takayuki Morimoto, Ryosuke Maeoka, Kengo Yamada, Ryosuke Matsuda, Mitsutoshi Nakamura, Fumihiko Nishimura, Shuichi Yamada, Young-Soo Park, Takahiro Tsujimura, et al. Characterization of HIF-1α knockout primary human natural killer cells including populations in allogeneic glioblastoma. International Journal of Molecular Sciences. 2024. 25. 11. 5896
Ryosuke Matsuda, Ryosuke Maeoka, Takayuki Morimoto, Tsutomu Nakazawa, Yudai Morisaki, Shohei Yokoyama, Masashi Kotsugi, Yasuhiro Takeshima, Shuichi Yamada, Fumihiko Nishimura, et al. Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator. Journal of Neuro-Oncology. 2024
Ryosuke Matsuda, Ryosuke Maeoka, Takayuki Morimoto, Tsutomu Nakazawa, Yudai Morisaki, Kenta Nakase, Shohei Yokoyama, Masashi Kotsugi, Yasuhiro Takeshima, Shuichi Yamada, et al. Preoperative blood counts predict overall survival in patients undergoing surgical removal of brain metastasis. World Neurosurgery. 2024
Takayuki Morimoto, Tsutomu Nakazawa, Ryosuke Maeoka, Ryosuke Matsuda, Mitsutoshi Nakamura, Fumihiko Nishimura, Shuichi Yamada, Ichiro Nakagawa, Young-Soo Park, Takahiro Tsujimura. Bulk RNA sequencing reveals the comprehensive genetic characteristics of human cord blood-derived natural killer cells. Regenerative therapy. 2024. 25. 367-376
CRISPR-Cas9-mediated TIM3 knockout in human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
(American Association of Immunology (AAI) "IMMUNOLOGY2021" 2021)
Efficient blockade of TIM3 by CRISPR-Cas9 in Human Natural killer cells Enhances an antitumor effect in Human Glioblastoma Cells.
(2020)
Characterization of a novel type NK cell line KHYG-1 carrying EGFRvIII-specific CAR in glioblastoma cells.
(American Association of Immunology (AAI) ”IMMUNOLOGY2020" 2020)